Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations

Clinical Trial Title: 
A phase III randomized trial for newly diagnosed high risk B-lymphoblastic leukemia (B-ALL) including a stratum evaluating dasatinib (IND#73789, NSC#732517) in patients with Ph-like tyrosine kinase inhibitor (TKI) sensitive mutations.
Clinical Trial Protocol ID: 
13020404-IRB01-AM11
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine if the administration of post-induction age adjusted intrathecal triple chemotherapy on an chemotherapy backbone will  improve 5-year DFS of children with high risk B-ALL compared to age adjusted intrathecal methotrexate.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are more than 365 days old and less than 31 years of age.
  • White blood cell count (WBC) criteria:
    • Are 1 to 9.99 years of age: WBC of 50,000/µL
    • Are 10 to 30.99 years of age: Any WBC
    • Are 1 to 30.99 years of age: Any WBC with:
      • Testicular leukemia
      • CNS leukemia (CNS3)
      • Steroid pretreatment

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane